However, the clinical importance of monitoring AT III as a biomarker has not been fully elucidated because low AT III supplementation (93.0–123.0%) did not improve clinical outcomes in patients with acute respiratory failure undergoing venovenous ECMO, although it may help reduce the imbalance between pro-coagulant and anticoagulant factors (9). This evidence concerns the gene SERPINC1 and respiratory failure.